Science

We believe that stabilized cell-permeating peptide therapeutics have the potential to become a major class of drugs for oncology and other diseases.

Scientific Publications

ALRN-6924

Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia, A. Carvajal, D. Ben Neriah, A. Senecal, L. Benard, V. Thiruthuvanathan, T. Yatsenko, S.-R. Narayanagari, J. C. Wheat, T. I. Todorova, K. M. Mitchell, C. Kenworthy, V. Guerlavais, D. A. Annis, B. Bartholdy, Britta Will, J. D. Anampa, I. Mantzaris, M. Aivado, R. H. Singer, R. A. Coleman, A.Verma, U. Steidl. Sci Transl Med. 2018, 10(436). pii: eaao3003

https://stm.sciencemag.org/content/10/436/eaao3003/tab-pdf

Article highlighted in The Hematologist

https://www.hematology.org/Thehematologist/Diffusion/8673.aspx

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models, S. Y. Ng, N. Yoshida, A. L. Christie, M. Ghandi, N. V. Dharia, J. Dempster, M. Murakami, K. Shigemori, S. N. Morrow, A. Van Scoyk, N. A. Cordero, K. E. Stevenson, M. Puligandla, B. Haas, C. Lo, R. Meyers, G. Gao, A. Cherniack, A. Louissaint JR, V. Nardi, A. R. Thorner, H. Long, X. Qiu, E. A. Morgan, D. M. Dorfman, D. Fiore, J. Jang, A. L. Epstein, A. Dogan, Y. Zhang, S. M. Horwitz, E. D. Jacobsen, S. Santiago, J.-G. Ren, Guerlavais, D. A. Annis, M. Aivado, M. N. Saleh, A. Mehta, A. Tsherniak, D. Root, F. Vazquez, W. C. Hahn, G. Inghirami, J. C. Aster, D. M. Weinstock, R. Koch, Nat Commun. 2018, 22, 9(1) : 2024 https://www.nature.com/articles/s41467-018-04356-9

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas

Funda Meric-Bernstam, Mansoor N. Saleh, Jeffrey R. Infante, Sanjay Goel, Gerald Steven Falchook, Geoffrey Shapiro, Ki Y Chung, Robert Martin Conry, David S. Hong, Judy Sing-Zan Wang, Ulrich Steidl, Loren D. Walensky, Vincent Guerlavais, Marie Payton, D. Allen Annis, Manuel Aivado, and Manish R. Patel. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J of Clin Oncol. 35:15_suppl, 2505-2505 (2017)

https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2505
https://investors.aileronrx.com/static-files/1bd4ccdb-c057-4aea-a83f-9076761ba416

Abstract highlighted in Journal Clinical Oncology (ASCO Special article)

https://ascopubs.org/doi/pdf/10.1200/JCO.2017.77.0446

MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Howard TP, Arnoff TE, Song MR, Giacomelli AO, Wang X, Hong AL, Dharia NV, Wang S, Vazquez F, Pham MT, Morgan AM, Wachter F, Bird GH, Kugener G, Oberlick EM, Rees MG, Tiv HL, Hwang JH, Walsh KH, Cook A, Krill-Burger JM, Tsherniak A, Gokhale PC, Park PJ, Stegmaier K, Walensky LD, Hahn WC, Roberts CWM. Cancer Res. 2019 ;79(9):2404-2414

http://cancerres.aacrjournals.org/content/79/9/2404.long

Spatial Profiling of Stapled α–helical Peptide Atsp-7041 In Mouse Whole-body Thin Tissue Sections Using Droplet-based Liquid Microjunction Surface Sampling-hplc-esi–ms/ms, V Kertesz, M Vavrek, C Freddo, G J Van Berkel, International Journal of Mass Spectrometry, 2019, 437, 17-22

https://www.sciencedirect.com/science/article/pii/S138738061730355X

Macrocyclic α helical peptide therapeutic modality: A perspective of learnings and challenges, Sawyer TK, Partridge AW, Kaan HYK, Juang YC, Lim S, Johannes C, Yuen TY, Verma C, Kannan S, Aronica P, Tan YS, Sherborne B, Ha S, Hochman J, Chen S, Surdi L, Peier A, Sauvagnat B, Dandliker PJ, Brown CJ, Ng S, Ferrer F, Lane DP. Bioorg Med Chem. 2018 ; 26(10) :2807-2815

https://www.sciencedirect.com/science/article/pii/S0968089618301743?via%3Dihub

Genome-scale CRI SPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. Stolte, A. Balboni Iniguez, N. V. Dharia, A. L. Robichaud, Amy Saur Conway, Ann M. Morgan, G. Alexe, N. J. Schauer, X. Liu, G. H. Bird, A. Tsherniak, F. Vazquez, S J. Buhrlage, L D. Walensky, and K Stegmaier. J Exp Med. 2018 ;215(8):2137-2155

http://jem.rupress.org/content/215/8/2137.long

Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99. Lee XA, Verma C, Sim AYL. 2017 ;85(8):1493-1506

https://onlinelibrary.wiley.com/doi/abs/10.1002/prot.25310

Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Wachter F, Morgan AM, Godes M, Mourtada R, Bird GH, Walensky LD. Oncogene 2017 ;36(15):2184-2190.

https://www.nature.com/articles/onc2016361

Toward Understanding the Molecular Recognition of Albumin by p53-Activating Stapled Peptide ATSP-7041. Tiwari G, Verma CS. J Phys Chem B. 2017 ;121(4):657-670

https://pubs.acs.org/doi/10.1021/acs.jpcb.6b09900

Advancements in Stapled Peptide Drug Discovery & Development, Guerlavais, T. K. Sawyer, Annual Reports in Medicinal Chemistry, Volume 49, 2014, 331–345.

https://www.sciencedirect.com/science/article/pii/B9780128001677000213

Macrocyclic α-helical peptide drug discovery, K. Sawyer, V. Guerlavais, K. Darlak, E. Feyfant, RSC Drug Discovery Series No. 40, Macrocycles in Drug Discovery, 2014, chapter 9, 339-366.

https://pubs.rsc.org/en/content/chapter/bk9781849737012-00339/978-1-84973-701-2

Design, Synthesis, Biophysical and Structure-Activity Properties of a Novel Dual MDM2 and MDMX Targeting Stapled α-Helical Peptide: ATSP-7041 Exhibits Potent In Vitro and In Vivo Efficacy in Xenograft Models of Human Cancer. Guerlavais, K. Darlak, B. Graves, C. Tovar, K. Packman, K. Olson, K. Kesavan, P. Gangurde, J. Horstick, A. Mukherjee, T. Baker, X.E. Shi, S. Lentini, K. Sun, S. Irwin, E. Feyfant, T. To, Z. Filipovic, C. Elkin, J. Pero, S. Santiago, T. Bruton, T. Sawyer, A. Annis, N. Fotouhi, T. Manning, H. Nash, L.T. Vassilev, Y.S. Chang and T.K. Sawyer. Proceedings of the 23rd American Peptide symposium, American Peptide Society, 2013, 217-218

https://www.americanpeptidesociety.org/assets/pdf-files/proceedings/23.pdf

Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Chang, Y.S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K. -H., Olson, K. A., Kesavan, K., Gangurde, P., Mukherjee, A., Baker, T., Darlak, K., Elkin, C., Filipovic, Z., Qureshi, F. Z., Cai, H., Berry, P., Feyfant, E., Shi, X. E., Horstick, J., Annis, D. A., Manning, A. M., Fotouhi, N., Nash, H., Vassilev, L. T. & Sawyer, T. K. Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci USA. 2013; 110(36):E3445-54.
http://www.pnas.org/content/early/2013/08/13/1303002110.full.pdf

A stapled p53 helix overcomes HDMX-mediated suppression of p53. Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G.M. & Walensky, L. D. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 18, 411-422 (2010).

https://www.cell.com/action/showPdf?pii=S1535-6108%2810%2900426-5

Article highlighted in Nature Reviews Drug Discovery http://www.nature.com/nrd/journal/v10/n1/full/nrd3342.html

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. J Am Chem Soc. 2007 Mar 7;129(9):2456-7

https://pubs.acs.org/doi/abs/10.1021/ja0693587




Scientific Events

AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 2019

Poster title: The Investigational Peptide Drug ALRN-6924, a Dual Inhibitor of MDMX and MDM2, is an Effective Myelopreservation Agent

http://share.aileronrx.com/posters/Aileron_AACR-NCI-EORTC_2019_Carvajal_Final.pdf

ESMO Congress 2019

Poster title: ALRN-6924 and Palbociclib in Patients with MDM2 Amplified or MDM2/CDK4 Co-amplified Tumors: Interim Analysis
http://share.aileronrx.com/posters/Aileron_ESMO_2019_Meric-Bernstam_Final.pdf

San Antonio Breast Cancer Symposium: 2018
60th ASH Annual Meeting And Exposition, 2018
EORTC/NCI/AACR Symposium Details

Poster Title: “Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies”
Session Name: Molecular Targeted Agents – PART II
Session Date: November 16th, 10:00 a.m.-2:00 p.m. local time
Location: The Convention Centre Dublin, Exhibition Hall

Society For Immunotherapy Of Cancer (SITC) Annual Meeting

Poster Title: The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models” 
Session Date: Nov. 9th, 8 a.m.– 8 p.m. and Nov. 10th, 8 a.m.– 8:30 p.m. local time
Location: Walter E. Washington Convention Center, Hall E

The Hematologist – ASH News And Reports

New Means to Reactivate p53 in Leukemia: A Stapled Peptide Inhibitor of MDMX and MDM2
July-August 2018, Volume 15, Issue 4
http://www.hematology.org/Thehematologist/Diffusion/8673.aspx

Dual Inhibition Of MDMX And MDM2 As A Therapeutic Strategy In Leukemia

Luis A. Carvajal1, Daniela Ben Neriah1, Adrien Senecal2, Lumie Benard1, Victor Thiruthuvanathan1, Tatyana Yatsenko1, Swathi-Rao Narayanagari1,3, Justin C. Wheat1, Tihomira I. Todorova1, Kelly Mitchell1, Charles Kenworthy2, Vincent Guerlavais4, D. Allen Annis4, Boris Bartholdy1, Britta Will1,3,5,6, Jesus D. Anampa5, Ioannis Mantzaris5, Manuel Aivado4, Robert H. Singer2, Robert A. Coleman2, Amit Verma3,5,6 and Ulrich Steidl1,3,5,6,*

1Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
2Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
3Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
4Aileron Therapeutics, Cambridge, MA 02139, USA.
5Division of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
6Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
↵*Corresponding author. Email: ulrich.steidl@einstein.yu.edu
Hide authors and affiliations

Science Translational Medicine  11 Apr 2018:
Vol. 10, Issue 436, eaao3003
DOI: 10.1126/scitranslmed.aao3003

Abstract: http://stm.sciencemag.org/cgi/content/abstract/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed

Reprint: http://stm.sciencemag.org/cgi/rapidpdf/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed

Full Text: http://stm.sciencemag.org/cgi/content/full/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed

ASH 2017 Presentation Details

Presentation Title:In Vitro and Preclinical In Vivo Evidence Support MDMX/MDM2 as Common Vulnerabilities Across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the Alpha-Helical P53 Stapled Peptide ALRN-6924”
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Targeted therapies for Non-Hodgkin’s Lymphomas
Session Date: Monday, December 11, 2017
Session Time: 7:00 a.m. – 8:30 a.m. EST
Presentation Time: 7:00 a.m. EST

Presentation Title“Dual Inhibition of MDMX and MDM2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia”
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Novel Therapeutics and Mechanisms of Resistance in Myeloid Disease
Session Date: Monday, December 11, 2017
Session Time: 4:30 p.m. – 6:00 p.m. EST
Presentation Time: 5:00 p.m. EST

Aileron Therapeutics At ASCO 2017 Annual Meeting

Oral Abstract Session: “Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas”
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Abstract #:2505

VIEW ABSTRACT
VIEW PRESENTATION




Reviews

Macrocyclic Peptides as PPI inhibitors

Cyclic peptide therapeutics: past, present and future. A. Zorzi, K. Deyle, Heinis, Current Opinion in Chemical Biology 2017, 38:24–29

https://www.sciencedirect.com/science/article/abs/pii/S1367593116302010?via%3Dihub

Stabilized helical peptides: overview of the technologies and its impact on drug discovery, Mark Klein. Expert Opinion on Drug Discovery, 2017, 12:11, 1117-1125

https://www.tandfonline.com/doi/abs/10.1080/17460441.2017.1372745?journalCode=iedc20

Protein epitope mimetic macrocycles as biopharmaceuticals, Luther A, Moehle K, Chevalier E, Dale G, Obrecht D. Curr Opin Chem Biol. 2017 ;38:45-51

https://www.sciencedirect.com/science/article/abs/pii/S1367593116301934?via%3Dihub

Peptides and peptidomimetics as regulators of protein-protein interactions. Cunningham AD, Qvit N, Mochly-Rosen D. Curr Opin Struct Biol. 2017; 44:59-66

https://www.sciencedirect.com/science/article/abs/pii/S0959440X16301300?via%3Dihub

New Modalities for Challenging Targets in Drug Discovery. Valeur E, Guéret SM, Adihou H, Gopalakrishnan R, Lemurell M, Waldmann H, Grossmann TN, Plowright AT. Angew Chem Int Ed Engl. 2017 ;56(35):10294-10323.

https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201611914

Reactivating p53 Tumor Suppressor

Impact of oncogenic pathways on evasion of antitumour immune responses, Spranger S, Gajewski TF, Nat Rev Cancer. 2018 ;18(3):139-147

https://www.nature.com/articles/nrc.2017.117

Exploiting the p53 Pathway for Therapy. Cheok CF, Lane D. Cold Spring Harb Perspect Med. 2017;7(3). pii: a026310).

http://perspectivesinmedicine.cshlp.org/content/7/3/a026310.long

Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. Cui Y, Guo G. Int J Mol Sci. 2016 ;17(11)

https://www.mdpi.com/1422-0067/17/11/1942

Emerging roles of p53 and other tumour-suppressor genes. Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Nat Rev Immunol. 2016;16(12):741-750

https://www.nature.com/articles/nri.2016.99

MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond, JC Marine, A. Jochemsen, Cold Spring Harb Perspect Med. 2016;6(7). pii: a026237

http://perspectivesinmedicine.cshlp.org/content/6/7/a026237.long

The Role of MDM2 Amplification and Overexpression in Tumorigenesis. Oliner JD, Saiki AY, Caenepeel S. Cold Spring Harb Perspect Med. 2016 ;6(6). pii: a026336.

http://perspectivesinmedicine.cshlp.org/content/6/6/a026336.long

Clinical Overview of MDM2/X-Targeted Therapies. Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Front Oncol. 2016 ;6:7.

https://www.frontiersin.org/articles/10.3389/fonc.2016.00007/full

The Roles of MDM2 and MDMX in Cancer, O. Karni-Schmidt, M. Lokshin, C. Prives, Annu. Rev. Pathol. Mech. Dis. 2016 11:617-44

https://www.annualreviews.org/doi/abs/10.1146/annurev-pathol-012414-040349?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=pathmechdis

p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Kruiswijk F, Labuschagne CF, Vousden KH, Nat Rev Mol Cell Biol. 2015 ;16(7):393-405

https://www.nature.com/articles/nrm4007

Unravelling mechanisms of p53-mediated tumour suppression. Bieging KT, Mello SS, Attardi LD, Nat Rev Cancer. 2014 ;14(5):359-70.

https://www.nature.com/articles/nrc3711

MDM2, MDMX and p53 in oncogenesis and cancer therapy. Wade M, Li YC, Wahl GM. Reviews Cancer. 2013;13(2):83-96.

https://www.nature.com/articles/nrc3430

Translating p53 into the clinic. Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. Nature Reviews Clinical Oncology. 2011;8(1):25-37

https://www.nature.com/articles/nrclinonc.2010.174